Dengue: the fever going down does not mean recovery – warning signs that need hospital care
The illness goes through 3 phases. The critical phase usually falls on days 4 to 7, just as the fever eases. Warning signs, home care and medicines…
Dengue virus belongs to the genus Flavivirus and has 4 serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. Infection with one serotype gives lifelong immunity to that serotype but only temporary protection of a few months against the others. A secondary infection with a different serotype increases the risk of severe disease through antibody-dependent enhancement (ADE). A new-generation vaccine, Qdenga (Takeda), is now available from 4 years of age and protects against all 4 serotypes.
Dengue virus belongs to the genus Flavivirus and has 4 serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. Infection with one serotype gives lifelong immunity to…
The illness goes through 3 phases. The critical phase usually falls on days 4 to 7, just as the fever eases. Warning signs, home care and medicines…
There are four dengue virus types. Having one type does not give lasting protection against the others, and old antibodies can make the next…
Qdenga has been licensed in Vietnam since May 2024 for people aged 4 and over. The 2-dose schedule 3 months apart, trial results, and who should not…
The key difference lies in the technology and the risk of ADE (antibody-dependent enhancement):
- Dengvaxia (Sanofi): uses a yellow fever 17D virus backbone. In people who have never had dengue (seronegative), the vaccine acts like a first natural infection. When such a person is later bitten by a mosquito and naturally infected with dengue, non-neutralising antibodies trigger ADE, causing the virus to multiply massively, which leads to severe dengue and more hospital admissions. WHO therefore requires a blood test to confirm previous dengue infection before Dengvaxia can be given.
- Qdenga (Takeda): uses a dengue type 2 virus backbone (strain PDK-53) and stimulates both neutralising antibodies and broad T cell-mediated immunity. A phase 3 clinical trial with 4.5 years of follow-up confirmed that Qdenga is safe and highly effective in BOTH PEOPLE WHO HAVE AND HAVE NOT HAD DENGUE, so NO screening test is needed before vaccination.
ADE (antibody-dependent enhancement) is the mechanism that explains why a second dengue infection is often more severe than the first. After recovering from one dengue type (for example DENV-1), the body has lifelong protective antibodies against DENV-1, but cross-reactive antibodies against the other types (DENV-2, 3, 4) fade after a few months. When a later mosquito bite causes infection with DENV-2, the old cross-reactive antibodies are not strong enough to neutralise the virus; instead they form complexes that bind to Fc gamma receptors on the surface of macrophages. This helps the new virus enter immune cells faster and multiply in huge numbers, causing a cytokine storm, increased capillary permeability and massive plasma leakage, which leads to shock and internal bleeding.
In dengue, the platelet count falls sharply and the blood vessel walls are damaged, so the risk of spontaneous bleeding is very high. Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen and diclofenac) inhibit platelet aggregation and irritate and ulcerate the stomach lining. Using them makes bleeding worse and can easily lead to massive gastrointestinal bleeding (vomiting blood, black stools), stomach perforation and death from blood loss. THE ONLY FEVER MEDICINE ALLOWED IS PARACETAMOL, at 10–15 mg/kg per dose (4–6 hours apart, no more than 60 mg/kg per day).
According to Ministry of Health guidance, a person with dengue must be taken to hospital immediately if any of the following warning signs appear (usually between day 3 and day 7 of the illness):
1. Severe abdominal pain, with increasing and continuous pain over the liver (below the right ribs).
2. Persistent vomiting (3 times in 1 hour or 4 times in 6 hours).
3. Mucosal bleeding: bleeding gums, nosebleeds that are hard to stop, vomiting blood, black stools, blood in the urine, abnormal vaginal bleeding.
4. Fluid around the lungs or in the abdomen (swollen abdomen, laboured breathing).
5. Lethargy, drowsiness, restlessness, irritability, or cold hands and feet with sweating.
6. Tests: a high haematocrit (Hct) together with a rapid fall in platelets to below 100,000/mm3.
According to professional guidance: Qdenga is a live attenuated vaccine. EXCEPT for yellow fever vaccine, Qdenga must NEVER BE GIVEN ON THE SAME DAY as other live attenuated vaccines (such as measles, mumps, rubella or chickenpox). The required interval between Qdenga and other live vaccines is at least 28 days (4 weeks), so that they do not reduce each other's immune response.
CONTRAINDICATED. Unlike many other vaccines, the Qdenga dengue vaccine is clearly labelled by the manufacturer Takeda and the Ministry of Health as CONTRAINDICATED in breastfeeding and pregnant women. Women of childbearing age should use effective contraception for at least 1 month after each Qdenga dose.